Want to join the conversation?
In 2Q16, $ITRI's non-GAAP EBITDA improved by 9.3 percentage points to 10.1%, with 5 percentage points of improvement due to the special warranty expense last year. Non-recurring costs like audit, legal and other professional services cost was $9MM plus. Effective tax rate was 34.2% in the quarter.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.